Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HP-2001
- Development stage
- Unknown
- Lead developer
- Huapu Shijiazhuang Pharmaceutical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
HP-2001 is a recombinant protein subunit vaccine candidate developed by Huapu Biotechnology for the prevention of Herpes Zoster (shingles). The vaccine is formulated with Huapu's proprietary CpG adjuvant, HP007, which is a synthetic oligonucleotide that acts as a Toll-like receptor 9 (TLR9) agonist. This adjuvant system is designed to activate innate immunity and specifically induce a potent Th1-type adaptive immune response, which is essential for providing protection against the reactivation of the Varicella-Zoster Virus (VZV). HP-2001 is currently in Phase 1 clinical development in China.
- Other names
- HP-2001 recombinant protein vaccineHP2001 recombinant protein vaccineHP 2001 recombinant protein vaccineHP-2001 Herpes Zoster vaccineHP2001 Herpes Zoster vaccineHP 2001 Herpes Zoster vaccine
02
Targets
gE (VZV glycoprotein E)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on HP-2001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HP-2001.